Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 5 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesRecruitingNCT05669430Phase 1/2 Report a problem
Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung CancerRecruitingNCT05655663Not applicable Report a problem
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05651594Phase 2 Report a problem
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3 Report a problem
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1 Report a problem
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1 Report a problem
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2 Report a problem
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerRecruitingNCT05570825Phase 2 Report a problem
Pembro With Radiation With or Without OlaparibRecruitingNCT05568550Phase 2 Report a problem
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.RecruitingNCT05547321Phase 1 Report a problem
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsRecruitingNCT05533697Phase 1/2 Report a problem
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2 Report a problem
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerRecruitingNCT05492682Phase 1 Report a problem
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingNCT05491226Phase 2 Report a problem
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerRecruitingNCT05491083Phase 1/2 Report a problem
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)RecruitingNCT05482893Phase 1/2 Report a problem
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver TransplantationRecruitingNCT05475613Phase 2 Report a problem
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05467748Phase 1/2 Report a problem
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal CancerRecruitingNCT05462236Phase 2 Report a problem
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2 Report a problem
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaRecruitingNCT05440708Phase 1/2 Report a problem
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesRecruitingNCT05438459Phase 1/2 Report a problem
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)RecruitingNCT05431270Phase 1/2 Report a problem
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung CancerRecruitingNCT05430009Phase 1 Report a problem
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract CancerRecruitingNCT05429697Phase 2/3 Report a problem
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint InhibitionNot yet recruitingNCT05425576Phase 2 Report a problem
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingNCT05422794Phase 1 Report a problem
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck CancerRecruitingNCT05420948Phase 2 Report a problem
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C MutationRecruitingNCT05410145Phase 1/2 Report a problem
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsRecruitingNCT05405595Phase 1/2 Report a problem
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsRecruitingNCT05394103Phase 1/2 Report a problem
A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingNCT05382559Phase 1 Report a problem
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabNot yet recruitingNCT05366062Phase 2 Report a problem
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1 Report a problem
ATATcH Alternating Treatment Plans for Advanced CancerRecruitingNCT05358548Phase 2 Report a problem
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersRecruitingNCT05356741Phase 1/2 Report a problem
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal CancerNot yet recruitingNCT05352165Not applicable Report a problem
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung CancerRecruitingNCT05344209Phase 2 Report a problem
Study of PAT in Patients With Solid Tumor CancersRecruitingNCT05338658Phase 1 Report a problem
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerRecruitingNCT05329532Phase 1/2 Report a problem
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingNCT05327686Phase 2 Report a problem
A Study in Patients With Advanced CancersRecruitingNCT05320588Phase 1/2 Report a problem
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2 Report a problem
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast CancerRecruitingNCT05318469Phase 1/2 Report a problem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingNCT05317858Phase 3 Report a problem
Phase 1 First-in-human Study of JS014RecruitingNCT05296772Phase 1 Report a problem
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsRecruitingNCT05280314Phase 2 Report a problem
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsRecruitingNCT05270213Phase 1 Report a problem
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2 Report a problem
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingNCT05256745Phase 1/2 Report a problem
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic CancerRecruitingNCT05232409Phase 1 Report a problem
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruitingNCT05231122Phase 2 Report a problem
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable DiseaseRecruitingNCT05229614Phase 2 Report a problem
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot StudyRecruitingNCT05222087Phase 1 Report a problem
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1 Report a problem
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid TumorsRecruitingNCT05205109Phase 1 Report a problem
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid TumorsRecruitingNCT05204862Phase 1/2 Report a problem
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingNCT05203172Phase 4 Report a problem
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerRecruitingNCT05187182Phase 1 Report a problem
RAPA-201 Therapy of Solid TumorsRecruitingNCT05144698Phase 1/2 Report a problem
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard TreatmentRecruitingNCT05126472Phase 1/2 Report a problem
First in Human Study of T3P-Y058-739 (T3P)RecruitingNCT05120596Phase 1/2 Report a problem
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemNot yet recruitingNCT05106127Phase 2 Report a problem
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsRecruitingNCT05101070Phase 1/2 Report a problem
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersRecruitingNCT05098132Phase 1/2 Report a problem
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1 Report a problem
Study of Pembrolizumab and M032 (NSC 733972)RecruitingNCT05084430Phase 1/2 Report a problem
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerNot yet recruitingNCT05077215Phase 3 Report a problem
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingNCT05067283Phase 1 Report a problem
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsRecruitingNCT05055908Phase 3 Report a problem
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCRecruitingNCT05047094Not applicable Report a problem
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingNCT05020860Phase 2 Report a problem
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 1 Report a problem
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerRecruitingNCT04991948Phase 1 Report a problem
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingNCT04977453Phase 1/2 Report a problem
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2 Report a problem
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerRecruitingNCT04946370Phase 1/2 Report a problem
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT04920617Phase 2 Report a problem
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2 Report a problem
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic CancerNot yet recruitingNCT04901741Phase 2 Report a problem
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2 Report a problem
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid TumoursRecruitingNCT04855435Phase 1 Report a problem
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.RecruitingNCT04839991Phase 1 Report a problem
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNGRecruitingNCT04790682Not applicable Report a problem
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067RecruitingNCT04787042Phase 1/2 Report a problem
Intra-tumor Injection of Drug-eluting Microspheres With Multiple DrugsRecruitingNCT04770207Phase 2 Report a problem
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First LineRecruitingNCT04764487Phase 3 Report a problem
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)RecruitingNCT04752826Phase 1/2 Report a problem
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck CancersRecruitingNCT04747054Phase 3 Report a problem
TATE and Pembrolizumab (MK3475) in mCRC and NSCLCRecruitingNCT04701476Phase 2 Report a problem
Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1 Report a problem
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin ToxicityRecruitingNCT04631731Phase 1/2 Report a problem
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Phase 2/3 Report a problem
Nodal Radiation Therapy for Sentinel Lymph Node Positive MelanomaRecruitingNCT04594187Phase 2 Report a problem
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingNCT04585750Phase 1/2 Report a problem
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)RecruitingNCT04555226Not applicable Report a problem
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV MelanomaRecruitingNCT04513028Not applicable Report a problem
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingNCT04510597Phase 3 Report a problem
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaRecruitingNCT04486781Phase 2 Report a problem
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsRecruitingNCT04443088Phase 1 Report a problem

← Pembrolizumab